News | August 06, 2024
Lupin receives USFDA approval for Prednisolone Acetate Ophthalmic Suspension USP
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
The product is bioequivalent and therapeutically equivalent to the reference listed drug
Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated
